Livatag doxorubicin Transdrug regulatory update

BioAlliance said FDA granted Fast Track designation to Livatag to treat hepatocellular carcinoma (HCC) after treatment with sorafenib. The nanoparticle formulation of doxorubicin is in the Phase III R...